Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SECuRE: 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA in mCRPC
NCT04868604Phase 2Recruiting
- Sponsor
- Clarity Pharmaceuticals
- Start
- Aug 2021
- Primary completion
- Sep 2026
- Modality
- Radiopharmaceutical, Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Cu-67 SAR-bisPSMA in prostate cancer (PCa), sponsored by Clarity Pharmaceuticals. Primary endpoints: Biodistribution of 64Cu-SAR-bisPSMA at 48 hours, Dosimetry of 64Cu-SAR-bisPSMA at 48 hours and 10 more. Started Aug 2021; status: recruiting.
02
Drugs
Cu-67 SAR-bisPSMA
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04868604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04868604.